Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..
April 01, 2024
Share
Bora Pharmaceuticals Co., LTD. (TWSE:6472) agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) for approximately $210 million on January 16, 2024.The closing of the transaction is subject to customary regulatory approvals, United States antitrust authorities and in accordance with other laws and regulations. As of January 17, 2024, Trading value of equity interest $160 million and $8 million upon the achievement of the conditions of Earnout, and the equivalent of $40 million value from Upsher-Smith separately through dividends or a repurchase of SAH shares held by Sawai Group. The expected closing date of the transaction is March 17, 2024. BDO Taiwan CPA Firm acted as accountant to Bora Pharmaceuticals. Benjamin Garrett, Allen Lefkowitz and Krystn Hammond of Stifel Financial Corp. (NYSE:SF) acted financial advisor to Sawai Group Holdings Co., Ltd. Andrew L. Bab, Rafael Kariyev, Peter F.G. Schuur, Henry Lebowitz, Paul D. Rubin, Melissa Runsten, Kim T. Le, M. Natasha Labovitz, Sidney P. Levinson of Debevoise & Plimpton LLP and Katten Muchin Rosenman LLP both acted as legal advisor to Sawai Group Holdings Co., Ltd.
Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) on April 1, 2024.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.